The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions

Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19

(2020) Leigh Turner   Cell Stem Cell

Identifying the Risks of Unproven Regenerative Medicine Therapies

(2020) Peter W. Marks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis

(2020) Aaron E. Miller et al.   JAMA Neurology

The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis

(2018) Paul S Knoepfler et al.   Regenerative Medicine

Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD

(2017) Ajay E. Kuriyan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clarifying Stem-Cell Therapy’s Benefits and Risks

(2017) Peter W. Marks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global Distribution of Businesses Marketing Stem Cell-Based Interventions

(2016) Israel Berger et al.   Cell Stem Cell

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

(2016) Leigh Turner et al.   Cell Stem Cell